UK Secures Zero-Tariff US Deal and Increases Medicine Investment to Accelerate Patient Access to Breakthrough Treatments
核心洞察
The UK has secured the world's first zero percent tariff on pharmaceutical exports to the US for at least three years, protecting £5 billion in annual exports and cementing the UK's position as a global life sciences hub.
The government will increase investment in innovative treatments by approximately 25% - the first major increase in over two decades - enabling NICE to approve breakthrough medicines previously declined on cost-effectiveness grounds.
Major pharmaceutical companies including Bristol Myers Squibb (搜索), Moderna, and BioNTech are investing billions in the UK, with Bristol Myers Squibb committing upwards of $500 million over five years across research, development, and manufacturing.
The United Kingdom has secured a landmark pharmaceuticals deal with the United States that establishes zero percent tariffs on UK pharmaceutical exports and significantly increases domestic investment in innovative medicines, positioning British patients among the first globally to access breakthrough treatments.
Zero-Tariff Access Protects UK Manufacturing
The UK has become the only country worldwide to secure zero percent tariffs on pharmaceutical exports to the US for at least three years, protecting £5 billion in annual exports. Business and Trade Secretary Peter Kyle emphasized that this "guarantees that UK pharmaceutical exports will enter the US tariff free, protecting jobs, boosting investment and paving the way for the UK to become a global hub for life sciences."
The agreement also secures preferential terms for UK medtech exports, ensuring no additional new tariffs on medical technology to unlock further investments and boost economic growth.
Historic Investment Increase in Medicine Pricing
The government announced it will invest approximately 25% more in innovative, safe, and effective treatments - the first major increase in over two decades. This expansion enables the National Institute for Health and Care Excellence (NICE) to approve medicines that deliver significant health improvements but might have previously been declined purely on cost-effectiveness grounds.
NICE will now apply new cost-effectiveness thresholds of £25,000 to £35,000 per quality-adjusted life year, increased from the previous standard range of £20,000 to £30,000. Science Minister Lord Vallance stated this change will help "get the best and most innovative treatments to patients right across the UK quickly."
Industry Commits Billions in UK Investment
Major pharmaceutical companies have responded with substantial investment commitments. Bristol Myers Squibb (搜索) Board Chair and CEO Chris Boerner announced the company "anticipates being able to invest upwards of $500 million over the next 5 years" across research, development, and manufacturing based on the UK's commitments and increased investment in innovative medicines.
The deal has secured confidence from other major firms including Moderna and BioNTech, which are investing billions in the UK, driving renewed confidence and supporting the government's ambition for the UK to become Europe's leading life sciences economy by 2030.
Early Access to Breakthrough Treatments
The UK has secured mitigations under the US 'Most Favoured Nation' drug pricing initiative, ensuring continued access to the latest treatments. This encourages pharmaceutical companies worldwide to prioritize the UK for early launches of new medicines, meaning British patients could be among the first globally to access breakthrough treatments.
The UK has demonstrated international leadership in early access to innovative drugs, delivering breakthrough medicines like Blenrep, a revolutionary blood cancer (搜索) therapy for multiple myeloma (搜索) which the NHS in England was the first health system worldwide to roll out, and Kimmtrak, the first-of-a-kind eye cancer (搜索) drug.
Patient Advocacy Groups Welcome Changes
Patient organizations have expressed strong support for the reforms. Dr Sophie Castell, Chief Executive at Myeloma UK (搜索), noted that "every day counts when you're living with the incurable blood cancer (搜索) myeloma so anything that brings medicines into the hands of patients faster and allows them to live better and longer lives is a hugely positive and welcome move."
Sarah Sleet, CEO of Asthma + Lung UK (搜索), welcomed the progress, stating that "raising the cost effectiveness thresholds and updating NICE's methods should make it easier for proven, high value treatments to reach the people who need them most."
Accelerating Clinical Trial Access
The changes build on recent Department of Health and Social Care plans to halve clinical trial approval times from 91 to 41 days, ensuring patients can participate in potentially life-changing research several weeks sooner. Dan Knowles, CEO of Brain Tumour Research (搜索), emphasized that "an invitation to access clinical trials should be an expectation for all cancer patients and the increase in life sciences net spend sets us firmly on the route to achieving this."
Industry Leadership Endorses Framework
Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry (ABPI (搜索)), described the deal as "an important step towards ensuring patients can access innovative medicines needed to improve wider NHS health outcomes" and noted it "should also put the UK in a stronger position to attract and retain global life science investment and advanced medicinal research."
Professor Andrew Morris, President of the Academy of Medical Sciences, welcomed the government's intention to increase investment in medicines, stating that "holding medicines to a higher standard than other health interventions has fundamentally undervalued their contribution to patient care."
The agreement forms part of the government's Life Sciences Sector Plan, backed by over £2 billion of investment and developed to ensure the UK remains at the forefront of medical innovation. Science and Technology Secretary Liz Kendall emphasized that the deal "will ensure UK patients get the cutting-edge medicines they need sooner, and our world-leading UK firms keep developing the treatments that can change lives."